AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Modeling HFpEF with hiPSC-Derived Heart Tissue Uncovers the Mechanism of SGLT2 Inhibitors

By Tani H, Tohyama S

Instructions: Despite the poor prognosis and increase in the number of patients with heart failure with preserved ejection fraction (HFpEF), its pathophysiological mechanisms remain unclear, and evidence regarding its treatment remains insufficient. Although the multiorgan and chronic nature of this syndrome has made it difficult to model in animals, in recent years, a reproducible HFpEF model has been established by administering a high-fat diet and L-N G -Nitro arginine methyl ester (L-NAME). Methods: Here, we aimed to reproduce HFpEF in vitro , by generating human engineered heart tissues (hEHTs) using human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs), epicardial cells (Epis), endothelial cells (ECs) and macrophages, and culturing the tissues under high fatty acid (FA) and L-NAME supplementation (Figure 1A). Results: The medium-loaded hEHTs showed a marked reduction in relaxation function while preserving contraction function (Figure 1B); secreted high levels of the heart failure (HF) marker, BNP (Figure 1C, D); had abnormal calcium transients (Figure 1D); and showed structural aspects of HF like fibrosis and collapsed mitochondria (Figure 1E, F). These results suggest that culturing under HFpEF conditions cause mild fibrosis of hEHTs, while preserving contraction function and only reducing relaxation function. After adding several existing HF drugs, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) improved the decline in relaxation function and contributed to an improvement in HFpEF (Figure 2A-C). A comprehensive microarray analysis demonstrated the activation of genes associated with fibrosis and inflammation in the HFpEF model and the anti-inflammatory effects of SGLT2i addition (Figure 2D, E). We have verified that the eNOS-cGMP-PKG pathway is downregulated in the HFpEF model and that this is restored by SGLT2i at the mRNA and protein levels (Figure 2F-H). We further confirmed the Na and Ca overload in the HFpEF model and the restoration with SGLT2i addition (Figure 2I). We identified the importance of ECs in these responses and also confirmed that the beneficial effects of SGLT2i on HFpEF were abolished in analyses using eNOS-KO hiPSC-ECs. These results suggest that the activation of eNOS in ECs is particularly important for the therapeutic effects of SGLT2i on HFpEF (Figure 3). Conclusions: Our findings are crucial in elucidating the pathogenesis and mechanisms of improvement of HFpEF, for which few treatments have been established. We believe this highly reproducible and useful experimental system would be useful in the future for the discovery of new HF treatments.

doi.org/10.1161/circ.154.suppl_1.6344Interventions

AgingResearch.News